Received: 21 June 2022
Accepted: 30 December 2022
First Online: 17 January 2023
: Informed consent was obtained from all subjects and from legal guardians of the minors. All experimental protocols were approved by the Institutional Review Boards in all countries and was conducted under Good Clinical Practice per the Helsinki Declaration. The study was approved by several Institutional Review Boards from different countries, and these are listed in Table InternalRef removed. South Africa: University of Witwatersrand Research Ethics Committee and South African Health Products Regulation. Botswana: Health Research and Development Committee, Harvard T.H. Chan School of Public Health Office of Regulatory Affairs and Research Compliance and Botswana Drug Regulatory Unit. India: Ethics Committee- B J Medical College and Sassoon General Hospitals. Tanzania: National Institute of Medical Research (NIMR). Thailand: The Human Experimentation Committee, Research Institute for Health Sciences, Chiang Mai University and Research Ethics Committee, Faculty of Medicine, Chiang Mai University. Zimbabwe: Medical Research council of Zimbabwe, Medicine Control Authority of Zimbabwe, Research Council of Zimbabwe and Joint Research Ethics Committee for the University of Zimbabwe College of Health Sciences and Parirenyatwa Group of Hospitals.The study only recruited subjects with capacity to give informed consent. During follow up, whilst some of the subjects developed some neurocognitive symptoms, none was serious enough to make diagnosis for neurocognitive disorder, hence informed consent from LARS was not required.
: Not applicable.
: The authors have no financial disclosures to report.